Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing.
Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Tsaousis GN, Pepe G, Bouzarelou D, Tsoulos N, Papathanasiou A, Ziogas D, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Giassas S, Natsiopoulos I, Papazisis K, Vasilaki-Antonatou M, Psyrri A, Koumarianou A, Matthaios D, Zairi E, Blidaru A, Banu E, Jinga DC, Laçin Ş, Özdoğan M, Papadopoulou E, Nasioulas G. Agiannitopoulos K, et al. Among authors: papazisis k. Cancers (Basel). 2023 Oct 30;15(21):5218. doi: 10.3390/cancers15215218. Cancers (Basel). 2023. PMID: 37958392 Free PMC article.
RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis.
Tsantikidi A, Papazisis K, Floros T, Gazouli M, Papadopoulou E, Tsaousis G, Nasioulas G, Mester A, Milan KP, Gozman B, Afrasanie V, Stanculeanu DL, Trifanescu O, Pescaru F, Militaru C, Papadimitriou C. Tsantikidi A, et al. Among authors: papazisis k. Oncol Lett. 2023 Sep 22;26(5):480. doi: 10.3892/ol.2023.14060. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37809048 Free PMC article.
The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.
Tsoulos N, Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Pepe G, Bouzarelou D, Papathanasiou A, Grigoriadis D, Tsaousis GN, Gogas H, Troupis T, Papazisis K, Natsiopoulos I, Venizelos V, Amarantidis K, Giassas S, Papadimitriou C, Fountzilas E, Stathoulopoulou M, Koumarianou A, Xepapadakis G, Blidaru A, Zob D, Voinea O, Özdoğan M, Ergören MÇ, Hegmane A, Papadopoulou E, Nasioulas G, Markopoulos C. Tsoulos N, et al. Among authors: papazisis k. Cancer Genomics Proteomics. 2024 Sep-Oct;21(5):448-463. doi: 10.21873/cgp.20463. Cancer Genomics Proteomics. 2024. PMID: 39191493 Free PMC article.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing.
Agiannitopoulos K, Pepe G, Tsaousis GN, Potska K, Bouzarelou D, Katseli A, Ntogka C, Meintani A, Tsoulos N, Giassas S, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Christodoulou C, Natsiopoulos I, Papazisis K, Vasilaki-Antonatou M, Kabletsas E, Psyrri A, Ziogas D, Lalla E, Koumarianou A, Anastasakou K, Papadimitriou C, Ozmen V, Tansan S, Kaban K, Ozatli T, Eniu DT, Chiorean A, Blidaru A, Rinsma M, Papadopoulou E, Nasioulas G. Agiannitopoulos K, et al. Among authors: papazisis k. Cancer Genomics Proteomics. 2023 Sep-Oct;20(5):448-455. doi: 10.21873/cgp.20396. Cancer Genomics Proteomics. 2023. PMID: 37643779 Free PMC article.
Ribociclib and palbociclib-induced erythema multiforme: a case report.
Vrana E, Mylona S, Bobos M, Kontovinis L, Papazisis K. Vrana E, et al. Among authors: papazisis k. Oxf Med Case Reports. 2022 Nov 24;2022(11):omac116. doi: 10.1093/omcr/omac116. eCollection 2022 Nov. Oxf Med Case Reports. 2022. PMID: 36447465 Free PMC article.
Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis.
Douganiotis G, Kesisis G, Lalla E, Korantzis I, Boukovinas I, Papazisis K. Douganiotis G, et al. Among authors: papazisis k. Cancer Diagn Progn. 2022 Sep 3;2(5):585-591. doi: 10.21873/cdp.10146. eCollection 2022 Sep-Oct. Cancer Diagn Progn. 2022. PMID: 36060026 Free PMC article.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
80 results